source
- Roche reports up to 30% shrinkage of chronic MS lesions with fenebrutinib, eyes FDA approvalRoche has filed for FDA approval of its BTK inhibitor fenebrutinib for both relapsing and primary progressive multiple sclerosis, after the agency accepted the submission. At the MSToronto2026 mee…
- Astellas partners with AI Proteins on $400M computational drug discovery dealAstellas Pharma of Japan has entered a partnership with Boston based AI Proteins to apply its computational design platform to drug discovery. AI Proteins builds miniproteins from scratch using ar…